Search Results
Apr 13, 2026, 17:23 ET Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
genetic level. The ability to shut down fat creation while activating fat metabolism differentiates GDNF from existing therapies, including GLP-1 agonists."SCIENTIFIC SUMMARY (HT-VA STUDY)The HT-VA study evaluated the effects of parenteral GDNF in a diet-induced obesity
More news about: Hoth Therapeutics, Inc.
Apr 13, 2026, 09:30 ET John Hancock Convenes Global Leaders in Longevity for Third Longer. Healthier. Better. Symposium in Boston
moving medicine from symptom management to curative intent, including immune cell design and genetic disease intervention.The GLP-1 inflection point: Dr. Giles Yeo and Dr. Ian Smith will explore the science of appetite, the evolving nutrition landscape, and the societal forces
More news about: John Hancock
Apr 13, 2026, 08:31 ET First Program Designed Specifically For Women On GLP-1 In Perimenopause Targets Muscle Loss And Metabolism After 40
as a result of GLP-1–induced weight loss, individuals can lose up to 40% of that weight from lean mass, raising concerns about muscle preservation and long-term metabolic health. Yet few programs address this directly."GLP-1 is being treated as
More news about: Cindi Stickle
Apr 13, 2026, 07:00 ET As GLP-1 Drugs Reshape Global Eating Habits, Meala FoodTech Bridges the Nutrition Gap with a Single-Ingredient Protein Solution
better texture, addressing the core formulation challenge of the GLP-1 eraHAIFA, Israel, April 13, 2026 /PRNewswire/ -- GLP-1 weight management therapies are changing how people eat. With adoption
More news about: Meala FoodTech
Apr 10, 2026, 13:56 ET Apomeds Enters the UK Market With Its Digital Healthcare Platform
tadalafil, all while ensuring privacy and convenience.Weight management offers access to a similarly strong growing sector. Demand for GLP-1 treatments such as Wegovy and Mounjaro has risen sharply, even as access in the UK remains limited and often costly. NHS England's staged rollout
More news about: Apo Global Ltd.
Apr 10, 2026, 08:30 ET MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
(OXM) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR),
More news about: MetaVia Inc.
Apr 10, 2026, 08:16 ET Clean Eatz Kitchen Publishes 2026 Gluten-Free Meal Delivery Comparison Ahead of Celiac Awareness Month
Kitchen offers chef-prepared, dietitian-designed frozen meals shipped nationwide. Meal plans include Weight Loss, High Protein, Gluten-Free, GLP-1, and Build Your Own, starting at $8.49 per meal. No subscriptions required. Always-free shipping on all meal plan orders. More at
More news about: CE Kitchen Inc
Apr 10, 2026, 07:30 ET Viking Therapeutics to Participate at Upcoming Investor Conferences
designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders.
More news about: Viking Therapeutics, Inc.
Apr 09, 2026, 17:43 ET /C O R R E C T I O N -- Sequel Brands/
from biomarker analysis, testing, and metabolic profiling, with personalized protocols incorporating solutions as they emerge – such as NAD, GLP-1, HRT, peptides, supplements, and IV therapies. Designed for both novices and wellness enthusiasts, these solutions will provide personalized insights
More news about: Sequel Brands
Apr 09, 2026, 17:14 ET Foundayo™ (orforglipron), la nueva pastilla GLP-1 de Lilly que se administra por vía oral para la pérdida de peso, ahora está disponible en Estados Unidos.
telemedicina, y está siendo distribuido a todas las farmacias minoristas de Estados Unidos.Foundayo, la única pastilla de GLP-1 para la pérdida de peso que se puede tomar una vez al día a cualquier hora sin restricciones de comida o agua, comienza a un precio de $25 al
More news about: Eli Lilly and Company
Apr 09, 2026, 16:06 ET Playa Bowls Launches Protein Clouds, a Heavenly High-Protein Superfood Smoothie and Bowl Line
New Smoothies and Bowls Deliver Protein, Fiber, Antioxidant-Rich Superfoods, and Lower Calories for High-Protein and GLP-1 GuestsBELMAR, N.J., April 9, 2026 /PRNewswire/ --
More news about: Playa Bowls
Apr 09, 2026, 15:26 ET Powered Research at ARVO 2026
Powered Research specializes in preclinical research in ophthalmology and oncology. Our staff has extensive expertise in the design and development of non-GLP preclinical data packages, including tolerability and pharmacology models, drug distribution studies, and custom experimental designs. We strive to design
More news about: Powered Research, LLC
Apr 09, 2026, 11:34 ET Disrupting Pharma Data: AI That Heals Overload Into Insight, With Jeffrey Freedman
budgets need to be spent on educating physicians," he says. "We don't want patients all the time coming to a doctor and saying, 'I need a GLP-1.' I want the doctor saying to a patient, 'You have these issues, let's talk about how to make you better.'" The bigger issue is not visibility alone,
More news about: Disruption Interruption
Apr 09, 2026, 10:16 ET Global Weight Loss and Obesity Management Market | 12.8% CAGR Growth Trajectory | Asia Pacific, North America Lead | Novo Nordisk, Eli Lilly, Medtronic Drive Integrated Care Evolution
https://www.futuremarketinsights.com/reports/sample/rep-gb-411Executive Insight for Decision MakersThe market is at a critical inflection point, where GLP-1 receptor agonists, minimally invasive procedures, and AI-driven personalized care are reshaping treatment paradigms. Decision makers who invest
More news about: Future Market Insights
Apr 09, 2026, 09:00 ET Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide
fastest-growing regions globally. Currently, the treatment penetration rate of GLP-1 drugs remains extremely low, indicating massive growth potential. As a mature market in the Asia-Pacific region, South Korea's GLP-1RA market size reached USD 526 million in 2025 and is expected to increase to
More news about: Gan & Lee Pharmaceuticals
Apr 09, 2026, 08:41 ET Choose Health Launches Comprehensive At-Home GLP-1 Monitoring Panels for Ozempic, Wegovy and Mounjaro Users
metabolic health, today announced the launch of the GLP-1 Health Monitoring Panels for the estimated 1 in 8 Americans currently taking GLP-1 receptor agonist medications. The launch comes as GLP-1 prescriptions have tripled since 2020 and the FDA approved
More news about: Choose Health
Apr 09, 2026, 08:10 ET 92% Awareness, 38% Interest Signal Next Wave of GLP-1 Adoption, Reach3 Insights Study Finds
that the impact of GLP-1s extends well beyond weight loss. In qualitative responses, users describe a shift in their relationship with food, including reduced cravings, less constant hunger and a greater sense of control over eating habits."Our research suggests that the use of GLP-1s changes people's
More news about: Reach3 Insights
Apr 09, 2026, 07:15 ET RO OFFERS ELI LILLY'S FOUNDAYO™, THE NEWEST GLP-1 INNOVATION
eligible patients can now access Foundayo™ (orforglipron) – Eli Lilly Company's newest oral GLP-1 innovation – on the Ro platform, adding to Ro's already comprehensive formulary of FDA-approved GLP-1s. Foundayo™ is a once daily oral treatment for adults with obesity or overweight with weight-related
More news about: Ro
Apr 09, 2026, 07:00 ET Regen Therapy Partners with Stealth Health to Bring Specialized Telemedicine Services and Longevity Programs to 3,000 Clinics--Powered by an Exclusive Scientific and Biologics Strategic Collaboration with ZEO ScientifiX
into their existing operations—allowing them to offer physician-guided consultations, compounded medications, hormone replacement therapy, GLP-1 weight management programs, therapeutic peptides, and broader longevity protocols without building in-house capabilities."Regen Therapy has
More news about: Stealth Health
Apr 09, 2026, 06:45 ET Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.
LillyDirect® and telehealth providers and is shipping to retail pharmacies nationwide Foundayo, the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions, starts at $25 per month with commercial coverage and
More news about: Eli Lilly and Company
Apr 08, 2026, 16:44 ET Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists
initiation of Thetis, a clinical trial evaluating NEREUS™ (tradipitant) for the prevention of vomiting in patients receiving glucagon-like peptide-1 (GLP-1) receptor agonist therapies. NEREUS™ was recently approved for the prevention of vomiting induced by motion.1
More news about: Vanda Pharmaceuticals Inc.
Apr 07, 2026, 16:29 ET ImpediMed Appoints Erik Anderson as Chief Executive Officer
The platform also supports structured cancer survivorship programs and medical weight management, including patients on GLP-1 therapies, by providing real-time, whole-body insights. Trusted by healthcare organizations and research institutions worldwide, ImpediMed is redefining
More news about: ImpediMed
Apr 07, 2026, 09:30 ET PRESS PASSES AVAILABLE FOR NUTRITION 2026 TO BE HELD JULY 25-28
including:the Dietary Guidelines for Americansthe nutritional and metabolic effects of GLP-1 therapiesthe regulation and safety of food additivesprotein consumption and dietary
More news about: American Society for Nutrition
Apr 07, 2026, 09:00 ET More Patients Open to Non-GLP-1 Obesity Treatments After Learning About Alternatives, Phenomix Survey Finds
around treatment choices.No clear consensus on GLP-1 use: Patients are split on who GLP-1s are best suited for, signaling broader confusion about how GLP-1s should be used in obesity care. Only 39% believe GLP-1s should be available to anyone seeking weight loss, while another
More news about: Phenomix Sciences
Apr 07, 2026, 09:00 ET Rightway Launches Care Complete Weight Management to Help Employers Maximize GLP-1 Investment
program effectiveness, manage costs, and demonstrate ROI on their GLP-1 investment.How Care Complete Weight Management works:Proactive outreach: Rightway identifies members on GLP-1s and initiates engagement.Dedicated clinical team: Each
More news about: Rightway